| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1; 2 The Scripps Research Institute, La Jolla, California 92037; and 3 Division of Cardiac Surgery,University of Toronto, Toronto, Ontario, Canada M5G 2C4
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The present study was designed to investigate the interaction between 5-methyltetrahydrofolate and tetrahydrobiopterin in modulating endothelial function. Tetrahydrobiopterin is a critical cofactor for nitric oxide synthase and maintains this enzyme as a nitric oxide- versus superoxide-producing enzyme. The structure of 5-methyltetrahydrofolate is similar to tetrahydrobiopterin and both agents have been shown to improve endothelium-dependent vasodilatation. We hypothesized that 5-methyltetrahydrofolate interacts with nitric oxide synthase in a fashion analogous, yet independent, of tetrahydrobiopterin to improve endothelial function. We demonstrate that 5-methyltetrahydrofolate binds the active site of nitric oxide synthase and mimics the orientation of tetrahydrobiopterin. Furthermore, 5-methyltetrahydrofolate attenuates superoxide production (induced by inhibition of tetrahydrobiopterin synthesis) and improves endothelial function in aortae isolated from tetrahydrobiopterin-deficient rats. We suggest that 5-methyltetrahydrofolate directly interacts with nitric oxide synthase to promote nitric oxide (vs. superoxide) production and improve endothelial function. 5-Methyltetrahydrofolate may represent an important strategy for intervention aimed at improving tetrahydrobiopterin bioavailability.
nitric oxide; folic acid
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
NITRIC OXIDE (NO) can be produced by three homodimeric isozymes, termed NO synthases (NOS), including endothelial NOS (eNOS), neuronal NOS, and inducible NOS. Under normal conditions, eNOS efficiently catalyzes electron transfer from nicotinamide adenine dinucleotide phosphate (reduced)-flavin adenine dinucleotide-flavin mononucleotide (NADPH-FAD-FMN) to L-arginine generating citrulline and NO. This cascade of electron transfer to L-arginine is dependent on the presence of tetrahydrobiopterin (BH4) bound within the active site. Conversely, eNOS devoid of BH4 leads to the uncoupling of electron transfer to L-arginine and facilitates the production of superoxide (4, 5, 28). Recent reports (10, 17, 22, 24, 25) indicate that supplementation with BH4 improves endothelium-dependent vasodilatation in experimental diabetes, models of ischemia and reperfusion injury, hypercholesterolemia, and cigarette smoking.
The structure of 5-methyltetrahydrofolate (5-MTHF) is extremely similar to that of BH4 with the exception of an extended tail attached to 5-MTHF. It has been proposed that the large size of 5-MTHF would exclude it from interacting with the active site of NOS (in a fashion similar to BH4). However, clinical data (22, 27) contradicts this argument because direct infusion of 5-MTHF into the brachial artery of patients with hyperlipidemia mimics the effects of BH4 on endothelial function. Stroes et al. (23) recently demonstrated that 5-MTHF augmented acetylcholine (ACh)-stimulated NO release in cultured endothelial cells. The authors further concluded that 5-MTHF was not acting as an antioxidant but directly interacting with eNOS.
The present study was designed to investigate the interaction among eNOS, BH4, and 5-MTHF. Specifically, we examined 1) the effects of 5-MTHF on BH4-inhibited superoxide and NO production, 2) the ability of 5-MTHF to directly interact with eNOS assessed by molecular computer modeling, and 3) the effect of 5-MTHF and BH4 on endothelial function in a BH4-deficient animal model. We herein report that 5-MTHF may interact with the active site of eNOS in a fashion analogous to BH4. In addition, 5-MTHF restores BH4-inhibited superoxide production. Finally, 5-MTHF exerts beneficial effects on endothelial function in a BH4 deficient animal model to a similar degree as BH4.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Superoxide production. Superoxide produced by bovine recombinant eNOS (isolated from baculovirus overexpression in Sf9 cells) (Cayman Chemical; Ann Arbor, MI) was measured with 250 µmol bis-N-methylacridinium (lucigenin) chemiluminescence. Recombinant eNOS (7.5 µg) was incubated with 10 µM FAD, 1 mM CaCl2, 1 mM NADPH, 300 U/ml calmodulin, and either 100 or 500 µM of 5-MTHF or BH4. Total photons produced by the reaction between superoxide and lucigenin were measured in a lumometer for 300 s. All chemicals were prepared immediately before use. eNOS was purchased from Cayman Chemical; all other reagents were obtained from Sigma (St. Louis, MO).
Immunohistochemistry. Immortalized and bovine endothelial cells were both stained positively for eNOS protein. Cells were grown on German glass coverslips and fixed with 10% formalin for 15 min. Slides were rinsed with 100 µM Tris buffer (pH 7.6, 0.1% Triton X-100) and incubated with 1:250 primary polyclonal IgG rabbit anti-NOS antibodies in Tris buffer containing 0.005% bovine serum albumin for 24 h at 4°C (n = 20; Santa Cruz Biotechnology, Santa Cruz, CA). Slides were then rinsed and incubated with anti-rabbit IgG cyanored conjugated in the aforementioned Tris buffer for 2 h at 4°C. Fluorescence was measured by an epifluorescence-equipped microscope.
Measurement of reactive oxygen species in cultured endothelial cells. Bovine aortic endothelial cells were isolated from aorta with 1 mg/ml collagenase in phosphate-buffered saline (PBS) and cultured in medium 199 containing 10% fetal calf serum (FCS) and 200 mM glutamine. Cells were then incubated in 5% FCS and treated for 24 h. All experiments were performed in cells between passages 2 and 6. After reaching confluence, the cells were loaded with 2 µM of the fluorescent probe dihydrorhodamine 123 for 30 min in FCS-free medium 199 and then stimulated with 10 µM ACh for an additional 30 min. Cells were rinsed, trypsinized, and resuspended in Hanks' balanced salt solution buffer (pH 7.2) and 5% FCS, and then centrifuged and resuspended in Hanks' buffer without FCS. Dihydrorhodamine 123 is irreversibly converted to the green fluorescent membrane impermeable compound rhodamine 123. Fluorescence-activated cell sorter procedure was carried out with a flow cytometer equipped with an ion argon laser emitting at 488 nm. Emission spectra were collected above 540 nm on 10,000 cells per sample in three separate experiments.
Measurement of superoxide production in cultured endothelial cells. Superoxide production was assessed using flow cytometry by comparing the mean dihydroethidine (DHE)-induced fluorescence of immortalized human EA.Hy926 endothelial line. Cells were cultured as previously mentioned and then incubated in serum-free medium 199 and 25 µM DHE and stimulated for another 30 min in 10 µM ACh. DHE reacts specifically with superoxide and is converted to ethidium. Cells were rinsed, trypsinised, resuspended in PBS buffer (pH 7.2) and 5% FCS, and then centrifuged and resuspended in PBS without FCS.
Computer modeling. Autodock version 3.0 was used to dock BH4 and 5-MTHF. Partial charges for each atom were assigned to the ligand and enzyme with the use of SYBYL version 6.7 (Tripos; St. Louis, MO). Cubic affinity grid maps centered on the pterin site of bovine eNOS (dimensions 21 × 21 × 21 Å, grid points spacing 0.35 Å) were calculated for each pterin atom type and electrostatics using autogrid. Rotatable bonds for the pterins were specified with the use of the Autotors tool in Autodock. The pterins were individually docked to the eNOS pterin site using the Lamarkian genetic algorithm to search the precomputed affinity maps for low-energy binding orientations. Each docking trial was initiated with a randomly generated population of 50 binding orientations and completed after 1.5 million energy evaluations had been performed. Because of the stochastic nature of the docking process, 10 docking trials were performed. The resulting orientations were clustered with a 0.5 Å tolerance and ranked according to binding energy predicted by docking. Independent results of both BH4 and 5-MTHF were compared with the crystal structure of eNOS containing bound BH4.
Experimental model of endothelial dysfunction and effects of 5-MTHF. Studies were conducted to assess the effect of BH4 and 5-MTHF on endothelial function in fructose-fed rats. Fructose-fed rats have been demonstrated to have lower BH4 levels and impaired endothelial function (20).
Male Sprague-Dawley rats (n = 14) were randomly assigned to control and fructose groups. The fructose group was administered a 60% fructose-enriched diet for a period of 6 wk, as described in Shinozaki et al. (20). After 6 wk, the rats were euthanized and the thoracic aortas removed for the isometric dose-response studies as described previously (1). After equilibration, the tissue was stimulated as follows: 1) cumulative dose-response curves (DRC) to phenylephrine (PE), 2) cumulative DRC to the endothelium-dependent vasodilator ACh in PE-preconstricted arteries, and 3) cumulative DRC to the endothelial-independent vasodilator sodium nitroprusside in PE-preconstricted arteries. These responses were repeated in the presence of BH4 (100 µM) and 5-MTHF (100 µM). Percent maximum relaxation (%Emax) was compared between groups by one-way ANOVA.| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Immunocytochemistry. Endothelial cells isolated from the local abattoir and the immortalized human Ea.Hy96 cell line expressed eNOS. Cyclosporin in both the bovine and human endothelial cells lines induced eNOS expression in endothelial cells as previously demonstrated (not shown). Incubation with an inhibitory peptide specific for the antibody-binding site on eNOS markedly reduced fluorescence, confirming specificity of the primary and minimal nonspecific secondary antibody binding (not shown).
Attenuation of free radical production from eNOS by 5-MTHF and
BH4.
Figure 1 depicts the effects of 5-MTHF
and BH4 on superoxide production (by recombinant eNOS)
assessed by lucigenin chemiluminescence. Native enzyme in the absence
of cofactors produced large amounts of superoxide. This signal was
completely abolished by superoxide dismutase. Importantly, both
BH4 and 5-MTHF caused a concentration-dependent attenuation
in superoxide production.
|
|
|
Computer modeling.
Both BH4 and 5-MTHF were docked in the eNOS active site and
their positions were compared with that of the original
BH4, as determined from the crystal structure (Fig.
4). The average atomic distance between
the top-ranked BH4 docking solutions was 1.26 and 1.01 Å,
respectively, accounting for 6 of 10 runs. Similarly, the docking
solution for 5-MTHF was within 1.4 Å (excluding the tail) of the
actual pterin-binding site. Moreover, the 5-MTHF was 
stacked with
Trp-449, which is consistent with Fischmann et al.
(7), who found a similar interaction between
BH4 and their analogous Trp-447. Furthermore, N3 and NA2 of
the docked 5-MTHF were aligned identically to the corresponding
BH4 atoms and were 3.1 and 3.0 Å from the propionate group
of heme, again similar to what was reported by Fischmann et al.
(7). Finally, the relative binding energies between
BH4 and 5-MTHF were 
16.92 and 13.96, respectively. The
interaction between 5-MTHF and the eNOS active site is illustrated in
Fig. 4. The actual pterin-binding site is overlaid with 5-MTHF for
reference.
|
Endothelial function assessment.
Figures 5 and
6 depict the effects of acute
BH4 and 5-MTHF treatments on vascular responses in
BH4-deficient fructose-fed rats. The fructose-fed
rats exhibited endothelial dysfunction; the
%Emax of ACh response was diminished in
fructose-fed versus control rat aortas. Importantly, both
BH4 and 5-MTHF improved ACh-mediated vasorelaxation to a
similar degree. Fructose-fed rats exhibited no changes in
endothelium-independent responses (to sodium nitroprusside) in the
presence or absence of BH4 or 5-MTHF (Figs. 5 and 6).
|
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
This is the first study to provide evidence indicating that 5-MTHF is capable of binding the pterin site in eNOS. Furthermore, this direct binding to eNOS mimics the orientation and interactions of the natural cofactor BH4. Our in vitro data also indicate that 5-MTHF prevents the exaggerated production of reactive oxygen species associated with a BH4 deficiency in both recombinant enzyme and in cultured endothelial cells. Finally, we demonstrated that 5-MTHF supplementation restores NO-dependent endothelial function in BH4-deficient fructose-fed rats.
It is well documented that BH4 alters eNOS activity. However, the exact mechanism and the role of BH4 in directing eNOS to produce NO instead of superoxide remain ill defined (2, 3, 13, 28). BH4 has been proposed to enhance the binding of L-arginine, activate heme into a high spin state, stabilize heme and donate electrons for the oxygenation reaction (2, 8). Various analogs of BH4 have also been reported to catalyze NOS activity. Interestingly, only fully reduced tetrahydro-analogs are active and support NO generation whereas the dihydrobiopterins are inhibitory. One such compound reported to maintain NOS activity is 5-methyl-BH4. Riethmuller et al. (19) recently demonstrated that 5-methyl-BH4 exhibited a markedly reduced activity toward free oxygen while at the same time maintained catalytic activity, favoring NO production by neuronal NOS. The authors speculated that the methyl group helped stabilize the pterin ring (19). These results support the notion that the methyl group on 5-MTHF, analogous to the methyl group in 5-methyl-BH4, will not interfere with interactions at the active site. The tetrahydro-reduced state of 5-MTHF also supports the observation that only the fully reduced analogs of BH4 remain catalytically active. The docking of 5-MTHF to eNOS in this study demonstrates that 5-MTHF is capable of fitting into the active site and can interact in an almost identical manner as the natural cofactor BH4.
Stroes et al. (23) recently demonstrated that 5-MTHF is unable to alter NOS activity in enzyme that is completely devoid of pterin. These observations do not support the concept that 5-MTHF can replace BH4 as a cofactor for NOS. The authors speculated that 5-MTHF could facilitate the one-electron oxidation of BH4, generating a pterin radical that may be necessary for the formation of NO (23). Such an interaction has been shown to exist between ascorbic acid and BH4 (12, 13). Although 5-MTHF can scavenge superoxide, its effects are several times lower than ascorbate. In addition, extracellular antioxidants such as superoxide dismutase are more relevant in vivo for scavenging superoxide compared with 5-MTHF (23).
The aforementioned paradigm may need to be reassessed in lieu of our data demonstrating that 5-MTHF is not only able to fit in the active site of eNOS but also mimic the orientation and interaction of BH4 and eNOS. It is, however, possible that 5-MTHF does not bind eNOS unless BH4 is already bound to the adjacent pterin-binding site. A similar relationship between BH4 has been shown to exist by Gorren et al. (9), who determined that the binding of the first BH4 has an anticooperative effect on the binding of the second BH4 (9). Such an interaction would be in line with the observation that 5-MTHF has no effect on eNOS activity unless some pterin is present.
Previous clinical studies (26, 27) and evidence from this study highlight the importance of 5-MTHF on reactive oxygen species produced by NOS. Our studies, and those of Verhaar et al. (27) and Wever et al. (28), have shown that 5-MTHF can attenuate superoxide production in recombinant eNOS. This observation indicates that 5-MTHF can directly interact with eNOS rather than having an independent cellular action such as lowering homocysteine, which could then possibly lower cellular oxidative stress. In addition, we have demonstrated that coincubation with DAHP and 5-MTHF or the BH4 precursor sepiapterin significantly lowers reactive oxygen species compared with cells incubated with DAHP alone (Fig. 2). Likewise, the superoxide-specific conversion of dihydroethidine to the fluorescent ethidium can be attenuated by coincubation with 5-MTHF.
The half-life of NO is dependent primarily on its reaction with superoxide or oxyhemoglobin (3). The reaction between NO and superoxide is extremely favorable, being three times more favorable than the reaction rate for superoxide and superoxide dismutase (3). Therefore, an eNOS enzyme partially deficient in BH4 or 5-MTHF facilitates the generation of the potent oxidant peroxynitrite. Furthermore, excess superoxide production can lead to the production of other oxidants such as hydrogen peroxide and hydroxyl radicals. We have demonstrated that 5-MTHF is capable of inhibiting superoxide production by recombinant NOS and by endothelial cells deficient in BH4. It can therefore be postulated that 5-MTHF binds and helps to convert NOS from a peroxynitrite synthase back to NOS.
Recent studies (11, 20) have indicated that
BH4 may be deficient in states of insulin resistance and
diabetes whereas eNOS expression is increased by insulin. This
combination of increased eNOS with the depletion of BH4
would favor eNOS-mediated superoxide production rather than NO.
Existing evidence suggests that the decreased NO production and
increased superoxide generation can be linked to insulin resistance.
Shinozaki et al. (21) have shown that endothelial
BH4 levels in fructose-fed rats were significantly decreased and that exogenous BH4 supplementation restored
NO production while simultaneously decreasing superoxide levels. Using
a different animal model, Pieper et al. (18) determined
that 5-methyl-BH4 could correct endothelial dysfunction in
streptozotocin-induced diabetic rats. In the present study, we
demonstrate 5-MTHF and BH4 restore endothelial function in
fructose-fed rats to an equal degree. Cellular changes in homocysteine
are not likely to account for the improved endothelial function given
that plasma homocysteine levels have been shown to be lower in diabetic
rats (15). Similarly, treatment with BH4 (10 mg · kg
1 · day1 for 8 wk)
in fructose-fed rats has recently been demonstrated to improve
endothelial function, insulin sensitivity and blood pressure
(21). All of these effects were attributed to the
restoration of eNOS function (21).
In summary, results from the present study demonstrate that 5-MTHF may interact with the active site of eNOS in a fashion analogous to BH4. 5-MTHF prevents increases in superoxide production from recombinant eNOS and endothelial cells. Finally, 5-MTHF improves endothelial function in BH4-deficient rat aortas. These data support the cellular and functional relationship between 5-MTHF, BH4, and endothelial function. 5-MTHF may be a useful strategy for interventions targeting BH4 bioavailability.
Study limitations. The results from our computer modeling suggest that 5-MTHF and BH4 bind in a similar fashion within the active site of eNOS. In addition, both have similar effects ameliorating superoxide and promoting vasodilation further supporting our hypothesis. However, we acknowledge that the modeling is not definitive and further investigations such as crytalography or kinetic enzyme-binding studies are essential.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Lawrence Ko for help in preparing the manuscript and Dr. C. J. Edgell for kindly donating the EA.hy926 cell line (Department of Pathology, University of North Carolina, Chapel Hill, NC). 5-Methyltetrahydrofolate used in the cell culture and animal experiments was kindly donated by EPROVA.
| |
FOOTNOTES |
|---|
This study was supported by the Heart and Stroke Foundation of Alberta (to T. J. Anderson and H. G. Parsons), Canadian Diabetes Association (to S. Verma and T. J. Anderson), Canadian Institute for Health Research (to S. Verma), and Alberta Heritage Foundation for Medical Research (to T. J. Anderson and S. Verma).
Address for reprint requests and other correspondence: S. Verma, Division of Cardiac Surgery, EN14-215, Toronto General Hospital, 200 Elizabeth St., Toronto, ON, Canada M5G 2C4 (E-mail: subodh.verma{at}sympatico.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published February 28, 2002;10.1152/ajpheart.00935.2001
Received 30 October 2001; accepted in final form 12 February 2002.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Arikawa, E,
Verma S,
Dumont AS,
and
McNeill JH.
Chronic bosentan treatment improves renal artery vascular function in diabetes.
J Hypertens
19:
803-812,
2001[ISI][Medline].
2.
Bec, N,
Gorren AFC,
Mayer B,
Schmidt PP,
Andersson KK,
and
Lange R.
The role of tetrahydrobiopterin in the activation of oxygen by nitric-oxide synthase.
J Inorg Biochem
81:
207-211,
2000[ISI][Medline].
3.
Beckman, JS,
and
Koppenol WH.
Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly.
Am J Physiol Cell Physiol
271:
C1424-C1437,
1996
4.
Cosentino, F,
and
Luscher TF.
Tetrahydrobiopterin and endothelial function.
Eur Heart J
19, Suppl:
G3-G8,
1998.
5.
Cosentino, F,
and
Luscher TF.
Tetrahydrobiopterin and endothelial nitric oxide synthase activity.
Cardiovasc Res
43:
274-278,
1999
6.
Crow, JP,
Beckman JS,
and
McCord JM.
Sensitivity of the essential zinc-thiolate moiety of yeast alcohol dehydrogenase to hypochlorite and peroxynitrite.
Biochemistry
34:
3544-3552,
1995[Medline].
7.
Fischmann, TO,
Hruza A,
Niu XD,
Fossetta JD,
Lunn CA,
Dolphin E,
Prongay AJ,
Reichert P,
Lundell DJ,
Narula SK,
and
Weber PC.
Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation.
Nat Struct Biol
6:
233-242,
1999[ISI][Medline].
8.
Gibraeil, HD,
Dittrich P,
Saleh S,
and
Mayer B.
Inhibition of endotoxin-induced vascular hyporeactivity by 4-amino-tetrahydrobiopterin.
Br J Pharmacol
131:
1757-1765,
2000[ISI][Medline].
9.
Gorren, AC,
List BM,
Schrammel A,
Pitters E,
Hemmens B,
Werner ER,
Schmidt K,
and
Mayer B.
Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites.
Biochemistry
35:
16735-16745,
1996[Medline].
10.
Heitzer, T,
Brockhoff C,
Mayer B,
Warnholtz A,
Mollnau H,
Henne S,
Meinertz T,
and
Munzel T.
Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase.
Circ Res
86:
E36-E41,
2000
11.
Heitzer, T,
Krohn K,
Albers S,
and
Meinertz T.
Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus.
Diabetologia
43:
1435-1438,
2000[ISI][Medline].
12.
Heller, R,
Munscher-Paulig F,
Grabner R,
and
Till U.
L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells.
J Biol Chem
274:
8254-8260,
1999
13.
Heller, R,
Unbehaun A,
Schellenberg B,
Mayer B,
Werner-Felmayer G,
and
Werner ER.
L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin.
J Biol Chem
276:
40-47,
2001
14.
Henderson, LM,
and
Chappell JB.
Dihydrorhodamine 123: a fluorescent probe for superoxide generation?
Eur J Biochem
217:
973-980,
1993[ISI][Medline].
15.
Jacobs, RL,
House JD,
Brosnan ME,
and
Brosnan JT.
Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat.
Diabetes
47:
1967-1970,
1998[Abstract].
16.
Kooy, NW,
Royall JA,
Ischiropoulos H,
and
Beckman JS.
Peroxynitrite-mediated oxidation of dihydrorhodamine 123.
Free Radic Biol Med
16:
149-156,
1994[ISI][Medline].
17.
Maier, W,
Cosentino F,
Lutolf RB,
Fleisch M,
Seiler C,
Hess OM,
Meier B,
and
Luscher TF.
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease.
J Cardiovasc Pharmacol
35:
173-178,
2000[ISI][Medline].
18.
Pieper, GM.
Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin.
J Cardiovasc Pharmacol
29:
8-15,
1997[ISI][Medline].
19.
Riethmuller, C,
Gorren AC,
Pitters E,
Hemmens B,
Habisch HJ,
Heales SJ,
Schmidt K,
Werner ER,
and
Mayer B.
Activation of neuronal nitric-oxide synthase by the 5-methyl analog of tetrahydrobiopterin. Functional evidence against reductive oxygen activation by the pterin cofactor.
J Biol Chem
274:
16047-16051,
1999
20.
Shinozaki, K,
Kashiwagi A,
Nishio Y,
Okamura T,
Yoshida Y,
Masada M,
Toda N,
and
Kikkawa R.
Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta.
Diabetes
48:
2437-2445,
1999[Abstract].
21.
Shinozaki, K,
Nishio Y,
Okamura T,
Yoshida Y,
Maegawa H,
Kojima H,
Masada M,
Toda N,
Kikkawa R,
and
Kashiwagi A.
Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats.
Circ Res
87:
566-573,
2000
22.
Stroes, E,
Kastelein J,
Cosentino F,
Erkelens W,
Wever R,
Koomans H,
Luscher T,
and
Rabelink T.
Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.
J Clin Invest
99:
41-46,
1997[ISI][Medline].
23.
Stroes, ES,
van Faassen EE,
Yo M,
Martasek P,
Boer P,
Govers R,
and
Rabelink TJ.
Folic acid reverts dysfunction of endothelial nitric oxide synthase.
Circ Res
86:
1129-1134,
2000
24.
Tiefenbacher, CP,
Chilian WM,
Mitchell M,
and
DeFily DV.
Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin.
Circulation
94:
1423-1429,
1996.
25.
Ueda, S,
Matsuoka H,
Miyazaki H,
Usui M,
Okuda S,
and
Imaizumi T.
Tetrahydrobiopterin restores endothelial function in long-term smokers.
J Am Coll Cardiol
35:
71-75,
2000
26.
Usui, M,
Matsuoka H,
Miyazaki H,
Ueda S,
Okuda S,
and
Imaizumi T.
Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid.
Clin Sci (Colch)
96:
235-239,
1999.
27.
Verhaar, MC,
Wever RM,
Kastelein JJ,
van Dam T,
Koomans HA,
and
Rabelink TJ.
5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia.
Circulation
97:
237-241,
1998.
28.
Wever, RMF,
van Dam T,
van Rijn HJ,
de Groot F,
and
Rabelink TJ.
Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase.
Biochem Biophys Res Commun
237:
340-344,
1997[ISI][Medline].
This article has been cited by other articles:
|
|
 |
|
  A. L. Moens, C. J. Vrints, M. J. Claeys, J.-P. Timmermans, H. C. Champion, and D. A. Kass Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H1971 - H1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Moens, H. C. Champion, M. J. Claeys, B. Tavazzi, P. M. Kaminski, M. S. Wolin, D. J. Borgonjon, L. Van Nassauw, A. Haile, M. Zviman, et al. High-Dose Folic Acid Pretreatment Blunts Cardiac Dysfunction During Ischemia Coupled to Maintenance of High-Energy Phosphates and Reduces Postreperfusion Injury Circulation, April 8, 2008; 117(14): 1810 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Baragetti, S. Raselli, A. Stucchi, V. Terraneo, S. Furiani, L. Buzzi, K. Garlaschelli, E. Alberghini, A. L. Catapano, and G. Buccianti Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3292 - 3297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Shirodaria, C. Antoniades, J. Lee, C. E. Jackson, M. D. Robson, J. M. Francis, S. J. Moat, C. Ratnatunga, R. Pillai, H. Refsum, et al. Global Improvement of Vascular Function and Redox State With Low-Dose Folic Acid: Implications for Folate Therapy in Patients With Coronary Artery Disease Circulation, May 1, 2007; 115(17): 2262 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Moens and D. A. Kass Tetrahydrobiopterin and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2439 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Antoniades, C. Shirodaria, N. Warrick, S. Cai, J. de Bono, J. Lee, P. Leeson, S. Neubauer, C. Ratnatunga, R. Pillai, et al. 5-Methyltetrahydrofolate Rapidly Improves Endothelial Function and Decreases Superoxide Production in Human Vessels: Effects on Vascular Tetrahydrobiopterin Availability and Endothelial Nitric Oxide Synthase Coupling Circulation, September 12, 2006; 114(11): 1193 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Anderson, Y.-H. Sun, J. Hubacek, M. E. Hyndman, S. Verma, L. Shewchuk, and N. Scott-Douglas Effects of folinic acid on forearm blood flow in patients with end-stage renal disease Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1927 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M Title, E. Ur, K. Giddens, M. J McQueen, and B. A Nassar Folic acid improves endothelial dysfunction in type 2 diabetes - an effect independent of homocysteine-lowering Vascular Medicine, May 1, 2006; 11(2): 101 - 109. [Abstract] [PDF]
|
|
|
|
 |
|
 C.-H. Wang, S.-H. Li, R. D. Weisel, P. W. M. Fedak, A. Hung, R.-K. Li, V. Rao, K. Hyland, W.-J. Cherng, L. Errett, et al. Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R299 - R304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.M.W. Spijkerman, Y.M. Smulders, P.J. Kostense, R.M.A. Henry, A. Becker, T. Teerlink, C. Jakobs, J.M. Dekker, G. Nijpels, R.J. Heine, et al. S-Adenosylmethionine and 5-Methyltetrahydrofolate Are Associated With Endothelial Function After Controlling for Confounding by Homocysteine: The Hoorn Study Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 778 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Werner, A. C.F. Gorren, R. Heller, G. Werner-Felmayer, and B. Mayer Tetrahydrobiopterin and Nitric Oxide: Mechanistic and Pharmacological Aspects Experimental Biology and Medicine, December 1, 2003; 228(11): 1291 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gori and J. D. Parker The Puzzle of Nitrate Tolerance: Pieces Smaller Than We Thought? Circulation, October 29, 2002; 106(18): 2404 - 2408. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
